Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 80 entries
View as:

A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS (MASTER-2)

Phase: N/A Priority: Normal
NCT ID: NCT03933202 Org: User:
Start: 07/22/19 End: 11/11/24 Due: 11/11/25

MSC2364447C Phase 1b in Systemic Lupus Erythematosus

Phase: N/A Priority: Normal
NCT ID: NCT02537028 Org: User:
Start: 11/30/15 End: 10/04/16 Due: 10/04/17

Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03704467 Org: User:
Start: 03/04/19 End: 11/06/19 Due: 11/06/20

Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy

Phase: N/A Priority: Normal
NCT ID: NCT02516813 Org: User:
Start: 09/15/15 End: 11/19/21 Due: 11/19/22

First in Human Study of M6223

Phase: N/A Priority: Normal
NCT ID: NCT04457778 Org: User:
Start: 07/10/20 End: 06/23/23 Due: 06/23/24

Study of M4344 in Combination With Niraparib

Phase: N/A Priority: Normal
NCT ID: NCT04655183 Org: User:
Start: 12/01/20 End: 09/01/23 Due: 09/01/24

The MS-LINK™ Outcomes Study

Phase: N/A Priority: Normal
NCT ID: NCT04735406 Org: User:
Start: 03/24/21 End: 05/31/24 Due: 05/31/25

Bintrafusp Alfa Program Rollover Study

Phase: N/A Priority: Normal
NCT ID: NCT05061823 Org: User:
Start: 12/01/21 End: 03/21/25 Due: 03/21/26

M8891 First in Human in Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03138538 Org: User:
Start: 08/08/17 End: 09/16/20 Due: 09/16/21

Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200)

Phase: N/A Priority: Normal
NCT ID: NCT02155647 Org: User:
Start: 07/03/14 End: 05/03/23 Due: 05/03/24

M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)

Phase: N/A Priority: Normal
NCT ID: NCT03631706 Org: User:
Start: 10/01/18 End: 06/25/24 Due: 06/25/25

CLARITY Extension Study

Phase: N/A Priority: Normal
NCT ID: NCT00641537 Org: User:
Start: 02/29/08 End: 12/31/11 Due: 12/31/12

M1231 in Participants With Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04695847 Org: User:
Start: 01/13/21 End: 06/23/23 Due: 06/23/24

Oral Cladribine in Early Multiple Sclerosis (MS)

Phase: N/A Priority: Normal
NCT ID: NCT00725985 Org: User:
Start: 12/31/08 End: 04/30/12 Due: 04/30/13

Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)

Phase: N/A Priority: Normal
NCT ID: NCT02625623 Org: User:
Start: 12/28/15 End: 11/13/19 Due: 11/13/20

M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)

Phase: N/A Priority: Normal
NCT ID: NCT03840902 Org: User:
Start: 04/16/19 End: 02/17/23 Due: 02/17/24

Study of Evobrutinib in Participants With RMS

Phase: N/A Priority: Normal
NCT ID: NCT04032171 Org: User:
Start: 09/10/19 End: 05/20/20 Due: 05/20/21

Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521)

Phase: N/A Priority: Normal
NCT ID: NCT06719973 Org: User:
Start: 05/14/25 End: 05/14/25 Due: 05/14/26

Study of M5049 in DM and PM Participants (NEPTUNIA)

Phase: N/A Priority: Normal
NCT ID: NCT05650567 Org: User:
Start: 01/19/23 End: 06/26/25 Due: 06/26/26

The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)

Phase: N/A Priority: Normal
NCT ID: NCT05162586 Org: User:
Start: 03/31/22 End: 11/20/24 Due: 11/20/25

Safety and Efficacy Study of M2951 in Participants With Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT02784106 Org: User:
Start: 07/31/16 End: 11/14/17 Due: 11/14/18

Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED)

Phase: N/A Priority: Normal
NCT ID: NCT03116971 Org: User:
Start: 05/25/17 End: 03/01/18 Due: 03/01/19

Efficacy and Safety of Atacicept in IgA Nephropathy

Phase: N/A Priority: Normal
NCT ID: NCT02808429 Org: User:
Start: 01/31/17 End: 02/07/20 Due: 02/07/21

Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)

Phase: N/A Priority: Normal
NCT ID: NCT06710132 Org: User:
Start: 01/29/25 End: 01/31/29 Due: 01/31/30

Met Non Small Cell Cancer Registry (MOMENT)

Phase: N/A Priority: Normal
NCT ID: NCT05376891 Org: User:
Start: 10/04/22 End: 03/31/27 Due: 03/31/28